Angion Biomedica is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics to address chronic and progressive fibrotic diseases. Co.'s product candidates and programs include ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, a ROCK2 preclinical program targeted towards the treatment of fibrotic diseases, a CYP11B2 preclinical program targeted towards diseases related to aldosterone synthase dysregulation, and a CYP26 (retinoic acid metabolism) inhibitor program targeted towards a number of indications, including cancer, and ANG-3777, a hepatocyte growth factor mimetic.